Schernthaner G
Diabetes Care. 1982 Nov-Dec;5 Suppl 2:114-8. doi: 10.2337/diacare.5.2.s114.
The affinity of human (recombinant DNA) insulin and porcine insulin to preformed IgG-insulin antibodies of insulin-treated diabetic individuals was studied in 29 insulin-treated diabetic patients. The binding of 125I-human insulin and 125I-porcine insulin with antibodies was similar in the group of patients without insulin resistance (N = 25). The sera of insulin-resistant diabetic patients (N = 4), containing very high IgG-insulin immunoglobulins, showed a significantly lower affinity for human insulin compared with porcine insulin (P less than 0.01). All four patients with insulin-antibody-mediated insulin resistance were positive for HLA-DR4, but negative for -DR3, supporting the concept of an immunogenetically transferred anti-insulin immune response in insulin-treated diabetic individuals. Based on the reduced binding of human insulin to IgG-antibodies of very high titers in patients with insulin resistance, a potential therapeutic advantage of human insulin therapy can be expected in such infrequent cases of immunologic insulin resistance.
在29例接受胰岛素治疗的糖尿病患者中,研究了人(重组DNA)胰岛素和猪胰岛素对胰岛素治疗的糖尿病个体预先形成的IgG-胰岛素抗体的亲和力。在无胰岛素抵抗的患者组(N = 25)中,125I-人胰岛素和125I-猪胰岛素与抗体的结合情况相似。胰岛素抵抗的糖尿病患者(N = 4)的血清中含有非常高的IgG-胰岛素免疫球蛋白,与猪胰岛素相比,对人胰岛素的亲和力显著降低(P < 0.01)。所有4例胰岛素抗体介导的胰岛素抵抗患者HLA-DR4呈阳性,但-DR3呈阴性,这支持了胰岛素治疗的糖尿病个体中存在免疫遗传传递的抗胰岛素免疫反应这一概念。基于胰岛素抵抗患者中人胰岛素与高滴度IgG抗体结合减少的情况,在这种罕见的免疫性胰岛素抵抗病例中,人胰岛素治疗可能具有潜在的治疗优势。